Earnings Name Insights: Insight Molecular Diagnostics (IMDX) Q1 2026 Administration View “Since submitting GraftAssureDx to the FDA in late March,…
Trending
- Oil struggles for direction as IEA flags greater volatility ahead, OPEC cuts demand forecast
- Oil edges up ahead of Trump-Xi meeting in Beijing
- Insight Molecular Diagnostics expects about $0.25M Q2 2026 revenue while projecting second-quarter cash burn above $9M (NASDAQ:IMDX)
- Dorit Kemsley’s Estranged Husband Drives Into New Neighborhood Drama Amid Bitter Divorce
- New Ukrainian laser weapon reportedly blinds surveillance systems
- Iran slams ‘collusion with Israel’ as Netanyahu reports ‘secret’ UAE visit
- Overseas Trails in the Sky 1st Chapter Sales Propel Falcom Profits to Insane Heights
- Sun move to Houston gets final approvals from WNBA, NBA